Sung Ho Lee, MD
Hematology & Oncology · Nyack, NYNPI 1841426780
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,592 of the $10,914 with a category attached, or 87.9%. It is spread thinly across 60 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations.
Across 493 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Johnson & Johnson$1K
- AstraZeneca$872
- Pfizer$604
- Merck$512
- AbbVie$485
- plus $6K from 54 others
Across 171 payments — averaging $7085.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$364K
- Merck$273K
- EMD Serono, Inc.$155K
- Boehringer Ingelheim$118K
- Pfizer$117K
- Janssen Research & Development, LLC$74K
- plus $111K from 5 others
What the payments were for
- Food & beverage$9,59288%
- Education$1,32212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$138
- Repatha$125
- VELCADE$111
How this compares
$10,914 in reported general payments places this provider in the 75th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 71 | $1,035,178 |
| EliquisApixaban | 178 | $181,202 |
| RevlimidLenalidomide | 12 | $150,472 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 28 | $61,950 |
| XareltoRivaroxaban | 32 | $48,542 |
| Anastrozole | 106 | $2,368 |
| Imatinib Mesylate | 25 | $1,359 |
| Letrozole | 20 | $687 |
| Hydroxyurea | 19 | $666 |
| ValacyclovirValacyclovir Hcl | 11 | $605 |
| Dexamethasone | 12 | $507 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 26 | $441 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 20 | $249 |
| Pantoprazole Sodium | 26 | $246 |
| Allopurinol | 17 | $243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $336 | $1,035,17871 claims |
| PfizerEliquis | $604 | $181,202178 claims |
| Bristol Myers SquibbRevlimid | $126 | $150,47212 claims |
| Johnson & JohnsonXarelto | $1,063 | $48,54232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Nyack
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.